Key Points Firefly Neuroscience will introduce NeuroSigma’s Monarch eTNS System to its nationwide network of clinicians who use the Evoke platform. Monarch is an FDA-cleared,…
Key Points Vistagen Therapeutics presented exploratory fasedienol data at Psych Congress 2026 in New Orleans. The analyses focused on participants with very severe social anxiety…
September 23, 2026
PRISM Mid-Day Movers: Mental Health and Aerospace & Defense are Today’s Leaders.
VistaGen Therapeutics (NASDAQ: VTGN) surged 53.94% to $0.387 after spiking as high as $0.5476, with trading volume exploding to roughly 498 million shares—far above its…
September 22, 2026
Vistagen Says Fasedienol Nasal Spray Showed Continued Improvement in Social Anxiety Extension Study
Key Points Vistagen released early results from a longer-term study of fasedienol nasal spray for people with social anxiety disorder. Participants could use the treatment…
Alzheimer’s disease starts long before anyone notices it. The changes in the brain that eventually show up as memory lapses, confusion or personality shifts can…
Key Points AbbVie presented new real-world VRAYLAR® results at Psych Congress 2026. Adults with major depressive disorder and bipolar I depression showed improvements in depression…
September 15, 2026
Enveric Secures New U.S. Patent Allowance for Non-Hallucinogenic PTSD Drug Candidates
Key Points Enveric Biosciences received a Notice of Allowance from the U.S. Patent and Trademark Office for compounds in its EVM401 drug-candidate series. The allowance…
Key Points Definium Therapeutics said its Phase 3 Panorama trial met its main goal and all key secondary efficacy endpoints in adults with generalized anxiety…
Key Points NRx Pharmaceuticals’ HOPE Therapeutics subsidiary is preparing to deploy Zeta Surgical’s FDA-cleared robotic transcranial magnetic stimulation, or TMS, system in Florida clinics. HOPE…
September 08, 2026
Compass Pathways Launches TRD Education Campaign at Psych Congress 2026
Key Points Compass Pathways will introduce its U.S. healthcare-provider education campaign, Change the Tune in TRD, at Psych Congress 2026 in New Orleans. The campaign focuses…
Key Points The FDA granted Breakthrough Therapy designation to Definium Therapeutics’ DT120 orally disintegrating tablet for major depressive disorder. The designation follows positive Phase 3…
QTREX Quantum (QTEX) is up 30.92% today to 1.175 from Tuesday’s 0.8975 close. The shares opened at 0.9105, rose as high as 1.35, and have…